Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
MannKind Corp (NASDAQ: MNKD) is trading significantly lower Monday morning after the company announced the FDA issued a complete response to United Therapeutics regarding the New Drug Application ...
Image source: The Motley Fool. MannKind (NASDAQ: MNKD) Q3 2024 Earnings Call Nov 07, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
After three quarters of positive earnings per share from Q3, 2023 through the first quarter of 2024 we had a net loss in the current quarter of $2 million, or $0.01 per share.
MannKind (MNKD) delivered earnings and revenue surprises of -25.00% and -2.48%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
For premium support please call: 800-290-4726 more ways to reach us